Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Compassionate Use of Dupilumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04776694
Expanded Access Status : Available
First Posted : March 2, 2021
Last Update Posted : June 14, 2021
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:
Provide Compassionate Use of Dupilumab

Condition or disease Intervention/treatment
Bullous Pemphigoid Eosinophilic Esophagitis (EoE) Pediatric Asthma Pediatric and Adolescent Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Pediatric Atopic Dermatitis Drug: Dupilumab

Detailed Description:
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.

Intervention Details:
  • Drug: Dupilumab
    Other Names:
    • REGN668
    • SAR231893

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04776694

Layout table for location contacts
Contact: Requests for compassionate use must be initiated by a treating physician. Physicians should contact 844-734-6643

Sponsors and Collaborators
Regeneron Pharmaceuticals
Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals Identifier: NCT04776694    
Other Study ID Numbers: R668-Dupilumab
First Posted: March 2, 2021    Key Record Dates
Last Update Posted: June 14, 2021
Last Verified: June 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Eosinophilic Esophagitis
Nasal Polyps
Dermatitis, Atopic
Pemphigoid, Bullous
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Leukocyte Disorders
Hematologic Diseases
Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Pathological Conditions, Anatomical
Skin Diseases, Vesiculobullous
Autoimmune Diseases